Trial Profile
Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Diabetic nephropathies; Heart failure; Obesity; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 04 Sep 2019 Status changed from recruiting to completed.
- 15 May 2019 Planned End Date changed from 1 May 2019 to 1 May 2020.
- 15 May 2019 Planned primary completion date changed from 1 May 2019 to 1 May 2020.